Circle Pharma Inc., of South San Francisco, said it raised $45 million in a series B financing led by The Column Group, with participation by Nextech Invest, through its Nextech VI Oncology SCSP fund. All investors from the prior round – Shangpharma, Lifeforce Capital and the Berkeley Catalyst Fund – joined the financing. Proceeds will be used to advance Circle’s work to develop inhibitors of cyclin A and cyclin E, and to expand the company’s pipeline. Peter Svennilson, founder and managing partner of The Column Group, and Thilo Schroeder, partner at Nextech Invest, were appointed to the board. John Josey, formerly president and CEO of Peloton Therapeutics Inc., was appointed to the board as chairman.

Compugen Ltd., of Holon, Israel, said it closed its public offering of about 8.3 million ordinary shares priced at $9 per share for gross proceeds of about $75 million. The company granted underwriters a 30-day option to purchase up to an additional 1.25 million shares, which has not yet been exercised. SVB Leerink and Stifel acted as joint book-running managers, while Suntrust Robinson Humphrey acted as lead manager and Oppenheimer & Co. acted as co-manager.

Eureka Therapeutics Inc., of Emeryville, Calif., said it closed a $45 million series E financing led by cell therapy company Lyell Immunopharma Inc., of South San Francisco, and joined by a syndicate of new and prior investors. The company will use proceeds to advance its TCR-mimic and antibody-TCR Artemis programs, including its anti-AFP Artemis phase I/II trial in the U.S. for hepatocellular carcinoma. In addition to the financing, Eureka and Lyell entered a collaboration to develop therapies against several undisclosed solid tumor targets expressed across multiple cancer types.

Keros Therapeutics Inc., of Lexington, Mass., has filed with the SEC for an IPO to raise up to $86 million. The number of shares and share price have not yet been disclosed. Jefferies, SVB Leerink and Piper Sandler are the joint bookrunners on the deal. Keros seeks a listing on Nasdaq under the symbol KROS. The company, founded in 2015 to focus on rare hematologic and musculoskeletal disorders, recently banked $56 million in a series C round.

Lattice Biologics Ltd., of Belgrade, Mont., said it arranged a nonbrokered private placement of up to 10 million units at 10 cents per unit for gross proceeds of $1 million. Each unit is composed of one common share and one-half transferrable share purchase warrant, with each full warrant entitling the subscriber to purchase one warrant share for a 24-month period following the closing date at an exercise price of 10 cents per share. Proceeds will be used to expand the company’s amniotic fluid-based stem cell technology, Amnioboost, in a trial assessing its effectiveness against COVID-19. The offering is expected to close on March 30, subject to acceptance by the TSX Venture Exchange, where shares of Lattice, which trades as LBV, gained CA9 cents on March 17 to close at CA$18 cents (US12 cents).

Rockwell Medical Inc., of Wixom, Mich., said it entered a debt financing agreement with an affiliate of Innovatus Capital Partners LLC to provide the company with up to $35 million in term loans. The first $22.5 million tranche was funded at closing, and Rockwell will be eligible to draw on a second tranche of $5 million upon achievement of certain milestones, including FDA approval of the NDA for I.V. Triferic. The company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Proceeds will be used for working capital purposes.

Seelos Therapeutics Inc., of New York, said it closed its public offering of 7.5 million shares at 60 cents apiece for net proceeds of about $3.9 million. Funds will be used for general corporate purposes and to advance the development of its product candidates. Benchmark Co. acted as sole book-running manager.

Sigilon Inc., of Cambridge, Mass., said it raised $80.3 million in a series B financing aimed at supporting a first-in-human trial of its encapsulated cell therapy for hemophilia A, expected to start in the first half of 2020, as well as continued advancement and expansion of Sigilon’s programs in rare blood disorders, lysosomal diseases and endocrine and immune disorders. Canada Pension Plan Investment Board, Longevity Vision Fund and funds managed by Blackrock joined founding investor Flagship Pioneering and other existing investors, including Indianapolis-based Eli Lilly and Co., in the financing round, which brings Sigilon’s total funding to more than $195 million.

Tiziana Life Sciences plc, of London and New York, said it closed its follow-on public offering of American depositary shares (ADSs), issuing about 3.3 million ADSs priced at $3 apiece, for gross proceeds of about $10 million. Tiziana also granted underwriters a 45-day option to purchase up to an additional 499,999 ADSs. The company intends to use the net proceeds to advance the clinical development of foralumab, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes. Thinkequity, a division of Fordham Financial Management Inc., acted as the sole book-running manager.